373
Views
39
CrossRef citations to date
0
Altmetric
Original Research

Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 4427-4438 | Published online: 14 Dec 2020

Figures & data

Figure 1 Schematic diagram of adverse drug events selection from Vigibase data used to filter the records.

Figure 1 Schematic diagram of adverse drug events selection from Vigibase data used to filter the records.

Table 1 Characteristics of Adverse Drug Events (194 ADEs Reported from 93 Individuals) Reported for Favipiravir in WHO Database

Table 2 Adverse Drug Events Suspected to Be Caused by Favipiravir, as Reported in the WHO Database (N=93)

Figure 2 Distribution of Adverse Drug events reported with Favipiravir use in COVID-19 across continents in Vigibase.

Figure 2 Distribution of Adverse Drug events reported with Favipiravir use in COVID-19 across continents in Vigibase.

Figure 3 Adverse drug event outcomes of Favipiravir use in COVID-19.

Figure 3 Adverse drug event outcomes of Favipiravir use in COVID-19.

Table 3 Distribution of Characteristics of Different Adverse Drug Events Suspected to Be Caused by Favipiravir Between Age <64 and >64 Years

Table 4 Comparison of Serious and Non-Serious Adverse Drug Events Suspected to Be Caused by Favipiravir Among Various Study Characteristics (N = 194)

Figure 4 System-wise distribution of ADEs attributed to Favipiravir use in COVID-19.

Figure 4 System-wise distribution of ADEs attributed to Favipiravir use in COVID-19.

Figure 5 Comparison of serious and non serious adverse drug events outcomes of Favipiravir use in COVID-19.

Figure 5 Comparison of serious and non serious adverse drug events outcomes of Favipiravir use in COVID-19.